Neurotensin and its receptors in the control of glucose homeostasis

Frontiers in Endocrinology

Volumn 3, Issue NOV, 2012, Pages

  Mazella, Jean ^a   Béraud Dufour, Sophie ^a   Devader, Christelle ^a   Massa, Fabienne ^a   Coppola, Thierry ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Beta cell; G protein coupled receptor; Neurotensin; Pancreas; Sortilin

Indexed keywords

EID: 84874357003     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00143     Document Type: Review

References (83)

1. Anlauf, M., Weihe, E., Hartschuh, W., Hamscher, G., and Feurle, G. E. (2000). Localization of xeninimmunoreactive cells in the duodenal mucosa of humans and various mammals. J. Histochem. Cytochem. 48,1617-1626.
2. Arnalich, F., Hernanz, A., Arribas, J. R., Codoceo, R., Grande, C., and Vazquez, J. J. (1990). Gut regulatorypeptidesandpancreaticbeta-cell response to nutritional stimuli in the elderly. J. Med. 21, 323-330.
3. Atoji, Y., Hirasawa, Y., Yamamoto, Y., and Suzuki, Y. (1995). Distribution ofneurotensin-immunoreactiveneurons in the digestive tract of the chicken. J. Auton. Nerv. Syst. 53, 185-194.
4. Bayer, V. E., Towle, A. C., and Pickel, V. M. (1991). Vesicular and cytoplasmic localization of neurotensin-like immunoreactivity (NTLI) inneurons postsynaptic to terminals containing NTLI and/or tyrosine hydroxylase in the rat central nucleus of the amygdala. J. Neurosci. Res. 30, 398-413.
5. Beraud-Dufour, S., Abderrahmani, A., Noel,J.,Brau,F.,Waeber,G.,Mazella, J., et al. (2010).Neurotensinisaregulatorofinsulinsecretioninpancreatic beta-cells. Int. J. Biochem. Cell Biol. 42,1681-1688.
6. Beraud-Dufour, S., Coppola, T., Massa, F., and Mazella, J. (2009). Neurotensin receptor-2 and -3 are crucial for the anti-apoptotic effect of neurotensin on pancreatic beta-TC3 cells. Int. J. Biochem. Cell Biol. 41, 2398-2402.
7. Brown, M., and Vale, W. (1976). Effects of neurotensin and substance P on plasma insulin,glucagon and glucose levels. Endocrinology 98,819-822.
8. Carraway, R., and Leeman, S. E. (1973). The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 248, 6854-6861.
9. Chabry, J., Gaudriault, G., Vincent, J. P., and Mazella, J. (1993). Implication of various forms of neurotensin receptors in the mechanism of internalization of neurotensin in cerebral neurons. J. Biol. Chem. 268, 17138- 17144.
10. Chalon,P.,Vita,N.,Kaghad,M.,Guillemot, M., Bonnin, J., Delpech, B., et al. (1996). Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 386, 91-94.
11. Choi, K. E., Hall, C. L., Sun, J. M., Wei, L., Mohamad, O., Dix, T. A., et al. (2012). A novel stroke therapy of pharmacologically inducedhypothermiaafterfocalcerebral ischemia in mice. FASEB J. 26, 2799-2810.
12. Chow, V. T., and Quek, H. H. (1996). HEP-COP, a novel human gene whose product is highly homologoustothealpha-subunitof theyeast coatomerproteincomplex.Gene 169, 223-227.
13. Coppola, T., Beraud-Dufour, S., Antoine, A., Vincent, J. P., and Mazella, J. (2008). Neurotensin protects pancreatic beta cells from apoptosis. Int. J. Biochem. Cell Biol. 40, 2296-2302.
14. Cui, H., Cai, F., and Belsham, D. D. (2006). Leptin signaling in neurotensin neurons involves STAT, MAP kinases ERK1/2, and p38 through c-Fos and ATF1. FASEB J. 20, 2654- 2656.
15. Desgraz, R., Bonal, C., and Herrera, P. L. (2011). Beta-cell regeneration: the pancreatic intrinsic faculty. Trends Endocrinol. Metab. 22,34-43.
16. Dicou, E., Vincent, J. P., and Mazella, J. (2004). Neurotensin receptor3/sortilin mediates neurotensininduced cytokine/chemokine expression in a murine microglial cell line. J. Neurosci. Res. 78, 92-99.
17. Dobner, P. R. (2005). Multitasking with neurotensin in the central nervous system. Cell.Mol.LifeSci.62, 1946- 1963.
18. Dolais-Kitabgi, J., Kitabgi, P., Brazeau, P., and Freychet, P. (1979). Effect of neurotensin on insulin, glucagon, and somatostatin release from isolated pancreatic islets. Endocrinology 105,256-260.
19. Dubuc, I., Sarret, P., Labbe-Jullie, C., Botto, J. M., Honore, E., Bourdel, E., et al. (1999). Identification of the receptor subtype involved in the analgesic effect of neurotensin. J. Neurosci. 19, 503-510.
20. Ehlers, R. A., Zhang, Y., Hellmich, M. R., and Evers, B. M. (2000). Neurotensin-mediated activation of MAPK pathways and AP-1 bindingin the human pancreatic cancer cellline, MIA PaCa-2. Biochem. Biophys. Res. Commun. 269, 704-708.
21. Elghazi, L., Balcazar, N., and BernalMizrachi, E. (2006). Emerging role of protein kinase B/Akt signaling in pancreatic beta-cell mass and function. Int. J. Biochem. Cell Biol. 38, 157-163.
22. Falciani, C., Lelli, B., Brunetti, J., Pileri, S., Cappelli, A., Pini, A., et al. (2010). Modular branched neurotensin peptides for tumor target tracing and receptor-mediated therapy: a proofof-concept.Curr.CancerDrugTargets 10,695-704.
23. Fernstrom, M. H., Mirski, M. A., Carraway, R. E., and Leeman, S. E. (1981). Immunoreactive neurotensin levels in pancreas: elevation in diabetic rats and mice. Metabolism 30, 853-855.
24. Feurle, G. E., Hamscher, G., Kusiek, R., Meyer, H. E., and Metzger, J. W. (1992). Identification of xenin, a xenopsin-related peptide, in the human gastric mucosa and its effect on exocrine pancreatic secretion. J. Biol. Chem. 267, 22305-22309.
25. Feurle, G. E., Metzger, J. W., Grudinki, A., and Hamscher, G. (2002). Interaction of xenin with the neurotensin receptor of guinea pigenteral smooth muscles. Peptides 23,1519-1525.
26. Feurle, G. E., Muller, B., and Rix, E. (1987). Neurotensin induces hyperplasia of the pancreas and growth of the gastric antrum in rats. Gut 28(Suppl.), 19-23.
27. Friess, H., Zhu, Z., Liard, V., Shi, X., Shrikhande, S. V., Wang, L., et al. (2003). Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab. Invest. 83,731-742.
28. Fujimoto, W. Y. (1981). Effect of gut peptides on glucose-stimulated insulin release by monolayer cultures of neonatal rat islet cells. Horm. Metab. Res. 13,135-138.
29. Goedert, M., and Emson, P. C. (1983). The regional distribution of neurotensin-like immunoreactivity in central and peripheral tissues of the cat. Brain Res. 272, 291-297.
30. Guha, S., Lunn, J. A., Santiskulvong, C., and Rozengurt, E. (2003). Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. Cancer Res. 63, 2379-2387.
31. Guha, S., Rey, O., and Rozengurt, E. (2002). Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res. 62, 1632- 1640.
32. Gui, X., and Carraway, R. E. (2001). Enhancement of jejunal absorption of conjugated bile acid by neurotensin in rats.Gastroenterology 120, 151-160.
33. Gui, X., and Carraway, R. E. (2004). Involvement of mast cells in basal and neurotensin-induced intestinal absorption of taurocholate in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G408-416.
34. Hadden, M. K., Orwig, K. S., Kokko, K. P., Mazella, J., and Dix, T. A. (2005). Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing nonnatural arginine and lysine residues. Neuropharmacology 49, 1149- 1159.
35. Hamscher, G., Meyer, H. E., and Feurle, G. E. (1996). Identification of proxenin as a precursor of the peptide xenin with sequence homology to yeast and mammalian coat protein alpha. Peptides 17, 889-893.
36. Hermey, G. (2009). The Vps10pdomain receptor family. Cell. Mol. Life Sci. 66,2677-2689.
37. Herzig, M. C., Chapman, W. G., Sheridan, A., Rake, J.B., and Woynarowski, J. M. (1999). Neurotensin receptor mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692. Anticancer Res. 19, 213-219.
38. Heuser, M., Kleiman, I., Popken, O., Nustede, R., and Post, S. (2002). Evidence for non-neurotensin receptormediated effects of xenin (1-25) - focus on intestinal microcirculation. Regul. Pept. 107, 23-27.
39. Hwang, J. R., Baek, M. W., Sim, J., Choi, H. S., Han, J. M., Kim, Y. L., et al. (2010). Intermolecular cross-talk between NTR1 and NTR2 neurotensin receptor promotes intracellular sequestration and functional inhibition of NTR1 receptors. Biochem. Biophys. Res. Commun. 391,1007-1013.
40. Iwase, K., Evers, B. M., Hellmich, M. R., Kim, H. J., Higashide, S., Gully, D., et al. (1997). Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692. Cancer 79,1787-1793.
41. Jequier, E. (2002). Leptin signaling, adiposity, and energy balance. Ann. N.Y. Acad. Sci. 967, 379-388.
42. Kalafatakis, K., and Triantafyllou, K. (2011). Contribution of neurotensin in the immune and neuroendocrine modulation of normal and abnormal enteric function. Regul. Pept. 170, 7-17.
43. Kaneto, A., Kaneko, T., Kajinuma, H., and Kosaka, K. (1978). Effects of substance P and neurotensin infused intrapancreatically on glucagon and insulin secretion. Endocrinology 102, 393-401.
44. Kim, E. R., Leckstrom, A., and Mizuno, T. M. (2008). Impaired anorectic effect of leptin in neurotensin receptor1-deficientmice. Behav. BrainRes. 194,66-71.
45. Kim, E. R., and Mizuno, T. M. (2010). Role of neurotensin receptor 1 in the regulation of food intake by neuromedins and neuromedinrelated peptides. Neurosci. Lett. 468, 64-67.
46. Kisfalvi, K., Guha, S., and Rozengurt, E. (2005). Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. J. Cell. Physiol. 202, 880-890.
47. Kitabgi, P. (2002). Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes. Curr. Opin. Drug Discov. Dev. 5, 764-776.
48. Kitabgi, P. (2006). Differential processing of pro-neurotensin/neuromedin N and relationship to pro-hormone convertases. Peptides 27, 2508-2514.
49. Kitabgi, P., Rostene, W., Dussaillant, M., Schotte, A., Laduron, P. M., and Vincent, J. P. (1987). Two populations of neurotensin binding sites in murine brain: discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution. Eur. J. Pharmacol. 140, 285-293.
50. Leeman, S. E., and Carraway, R. E. (1982). Neurotensin: discovery, isolation, characterization, synthesis and possible physiological roles. Ann. N. Y. Acad. Sci. 400,1-16.
51. Leinninger, G. M., Opland, D. M., Jo, Y. H., Faouzi, M., Christensen, L., Cappellucci, L. A., et al. (2011). Leptin action via neurotensin neurons controls orexin, the mesolimbic dopamine system and energy balance. Cell Metab. 14,313-323.
52. Lin, B. Z., Pilch, P. F., and Kandror, K. V. (1997). Sortilin is a major protein component of Glut4-containing vesicles. J. Biol. Chem. 272, 24145- 24147.
53. Martin, S., Navarro, V., Vincent, J. P., and Mazella, J. (2002). Neurotensin receptor-1and-3complexmodulates the cellular signaling of neurotensin in the HT29 cell line. Gastroenterology 123,1135-1143.
54. Martin, S., Vincent, J. P., and Mazella, J. (2003). Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia. J. Neurosci. 23, 1198-1205.
55. Mazella, J. (2001). Sortilin/neurotensin receptor-3: a new tool to investigate neurotensin signaling and cellular trafficking? Cell Signal. 13,1-6.
56. Mazella, J., Botto, J. M., Guillemare, E., Coppola, T., Sarret, P., and Vincent, J. P. (1996). Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J. Neurosci. 16, 5613-5620.
57. Mazella,J.,Petrault,O.,Lucas,G.,Deval, E., Beraud-Dufour, S., Gandin, C., et al. (2010). Spadin, a sortilinderived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol. 8, e1000355. doi: 10.1371/ journal.pbio.1000355
58. Mazella, J., Zsurger, N., Navarro, V., Chabry, J., Kaghad, M., Caput, D., et al. (1998). The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J. Biol. Chem. 273, 26273-26276.
59. Mijatovic, T., Gailly, P., Mathieu, V., De Neve, N., Yeaton, P., Kiss, R., et al. (2007). Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration. Cell. Oncol. 29, 315-326.
60. Munck Petersen, C., Nielsen, M. S., Jacobsen, C., Tauris, J., Jacobsen, L., Gliemann, J., et al. (1999). Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. EMBO J. 18, 595-604.
61. Myers, R. M., Shearman, J. W., Kitching, M. O., Ramos-Montoya, A., Neal, D. E., and Ley, S. V. (2009). Cancer, chemistry, and the cell: molecules that interact with the neurotensinreceptors.ACSChem.Biol.4, 503-525.
62. Nagai, K., and Frohman, L. A. (1978). Neurotensin hyperglycemia: evidence for histamine mediation andtheassessmentofapossiblephysiologic role. Diabetes 27,577-582.
63. Navarro, V., Martin, S., Sarret, P., Nielsen, M. S., Petersen, C. M., Vincent, J., et al. (2001).Pharmacological properties of the mouse neurotensin receptor 3. Maintenance of cell surface receptor during internalization of neurotensin. FEBS Lett. 495, 100-105.
64. Petersen, C. M., Nielsen, M. S., Nykjaer, A., Jacobsen, L., Tommerup, N., Rasmussen, H. H., et al. (1997). Molecular identification of a novel candidate sorting receptor purified from human brain by receptorassociated protein affinity chromatography. J. Biol. Chem. 272, 3599-3605.
65. Popp, E., Schneider, A., Vogel, P., Teschendorf, P., and Bottiger, B. W. (2007). Time course of the hypothermic response to continuously administered neurotensin. Neuropeptides 41,349-354.
66. Reubi, J. C., Waser, B., Friess, H., Buchler, M., and Laissue, J. (1998). Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 42, 546-550.
67. Rosell, S., and Rokaeus, A. (1979). The effect of ingestion of amino acids, glucose and fat on circulatingneurotensin-likeimmunoreactivity (NTLI) in man. Acta Physiol. Scand. 107,263-267.
68. Rostene, W. H., and Alexander, M. J. (1997). Neurotensin and neuroendocrine regulation. Front. Neuroendocrinol. 18, 115-173.
69. Ryder, N. M., Guha, S., Hines, O. J., Reber, H. A., and Rozengurt, E. (2001). G protein-coupled receptor signaling in human ductal pancreatic cancer cells: neurotensin responsiveness and mitogenic stimulation. J. Cell. Physiol. 186, 53-64.
70. Service, F. J., Jay, J. M., Rizza, R. A., O'Brien, P. C., and Go, V. L. (1986). Neurotensin in diabetes and obesity. Regul. Pept. 14, 85-92.
71. Shi, J., and Kandror, K. V. (2007). The luminal Vps10p domain of sortilin plays the predominant role in targeting to insulin-responsive Glut4containing vesicles. J.BiolChem. 282, 9008-9016.
72. Smith, K. E., Boules, M., Williams, K., and Richelson, E. (2012). NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain. Behav. Brain Res. 232,93-97.
73. Stolakis, V., Kalafatakis, K., Botis, J., Zarros, A., and Liapi, C. (2010). Theregulatoryroleofneurotensinon the hypothalamic-anterior pituitary axons: emphasis on the control of thyroid-related functions. Neuropeptides 44, 1-7.
74. Studler, J. M., Kitabgi, P., Tramu, G., Herve, D., Glowinski, J., and Tassin, J. P. (1988). Extensive co-localization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons. Neuropeptides 11, 95-100.
75. Taylor,A. I., Irwin, N., McKillop,A. M., Patterson, S., Flatt, P. R., and Gault, V.A. (2010). Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety. J. Endocrinol. 207, 87-93.
76. Thomas, R. P., Hellmich, M. R., Townsend, C. M. Jr., and Evers, B. M. (2003). Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr. Rev. 24,571-599.
77. Uhl, G. R., and Snyder, S. H. (1976). Regional and subcellular distributions of brain neurotensin. Life Sci. 19, 1827-1832.
78. Vincent, J. P., Mazella, J., and Kitabgi, P. (1999).Neurotensin and neurotensin receptors. Trends Pharmacol. Sci. 20, 302-309.
79. Wang, L., Friess, H., Zhu, Z., Graber, H., Zimmermann, A., Korc, M., et al. (2000). Neurotensin receptor1 mRNA analysis in normal pancreas and pancreatic disease. Clin. Cancer Res. 6,566-571.
80. Wice, B. M., Reeds, D. N., Tran, H. D., Crimmins, D. L., Patterson, B. W., Dunai, J., et al. (2012). Xenin25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes. Diabetes 61, 1793- 1800.
81. Wice, B. M., Wang, S., Crimmins, D. L.,Diggs-Andrews,K.A.,Althage,M. C., Ford, E. L., et al. (2010). Xenin25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism. J. Biol. Chem. 285, 19842-19853.
82. Wood, J. G., Hoang, H. D., Bussjaeger, L. J., and Solomon, T. E. (1988). Effect of neurotensin on pancreatic and gastric secretion and growth in rats. Pancreas 3,332-339.
83. Zsurger, N., Chabry, J., Coquerel, A., and Vincent, J. P. (1992). Ontogenesis and binding properties of high-affinity neurotensin receptors in human brain. Brain Res. 586, 303-310.